FindMyKOL
Clinical trialNCT04795219Active, not recruitingObservational

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219 is an observational study sponsored by University of California, San Francisco. As of 21 Nov 2026, it is active and no longer recruiting. It studies Hiv, NAFLD and 1 more condition. The registry lists an enrollment of 1,250 participants at 8 sites in 1 country. The registry lists a start date of 19 Jul 2021 and a primary completion date of 1 Sept 2031. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04795219
FieldValue
Registry IDNCT04795219
StatusActive not recruiting
Study typeObservational study
Lead sponsorUniversity of California, San Francisco
Enrollment1,250
Registered sites8
Countries1
ConditionsHiv, NAFLD and NAFLD-HIV
Start19 Jul 2021
Primary completion1 Sept 2031
Study completion30 Sept 2031
Last update posted23 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. NAFLD is the most common liver disease in US adults and the second leading cause for liver transplantation in the US. The natural history of NAFLD in the general population has been well described, with those with non-alcoholic fatty liver (NAFL, or simple steatosis) destined to have rare incidence of hepatic events compared to those with non-alcoholic steatohepatitis (NASH), who are at high risk for future development of cirrhosis, liver cancer and liver failure. The NASH Clinical Research Network (NASH CRN) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002, through the mechanism of RFA-DK-01-025, to further the understanding of diagnosis, mechanisms, progression and therapies of NASH. The NASH CRN effort has resulted in numerous seminal studies in the field. However, NASH CRN studies have systematically excluded persons living with HIV (PLWH), as NAFLD in these persons was thought to be different from that in the general population due to HIV, ART, concomitant medications, and co-infections. This has resulted in major knowledge gaps regarding NAFLD in the setting of HIV. This ancillary study of NAFLD and NASH in Adults with HIV (HIV NASH CRN), HNC 001 goal is to examine the prevalence of hepatic steatosis and NAFLD in a large, multicenter, and multiethnic cohort of PLWH (Steatosis in HIV Study)

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States1 site
  • University of Alabama

    Tuscaloosa

California, United States2 sites
  • University of California, San Diego

    La Jolla

  • University of California, San Francisco

    San Francisco

Indiana, United States1 site
  • Indiana University School of Medicine

    Indianapolis

Maryland, United States1 site
  • John Hopkins University

    Baltimore

North Carolina, United States1 site
  • Duke University

    Durham

Texas, United States1 site
  • University of Texas

    Houston

Virginia, United States1 site
  • Virginia Commonwealth University

    Richmond

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndiana: 1 siteIN1OhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 2 sitesCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 1 siteVA1Maryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabama: 1 siteAL1GeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04795219

Each answer restates registry values shown on this page.

What is NCT04795219?

NCT04795219 is an observational study sponsored by University of California, San Francisco. It studies Hiv, NAFLD and 1 more condition.

Is NCT04795219 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04795219?

The registry names Jennifer Price, MD, PhD (principal investigator, University of California, San Francisco) and Jordan Lake, MD, MSc (principal investigator, University of Texas) as overall officials.

Where does NCT04795219 run?

The registry lists 8 sites in 1 country. Every site with a stated country is in one country: United States.

When is NCT04795219 expected to complete?

The registry lists a primary completion date of 1 Sept 2031 and a study completion date of 30 Sept 2031. The sponsor last updated the record on 23 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.